About Us

LCT implants healthy cells to replace or repair damaged organs without the use of toxic drugs.

LCT – A Market Leader

1. LCT is at the forefront of the xeno-cell therapy industry.
2. DiabeCell^® Type 1 diabetes treatment has been approved for
   a Phase I/IIA clinical trial in Russia.
3. LCT's proprietary micro-encapsulation technology eliminates the need for immunosuppression.
4. Lead position in assessing choroid plexus cells for neurodegenerative diseases.
5. Long-term safety of insulin producing cells in a diabetes patient (after 9 years).
6. Own facilities/manufacturing - access to highest quality cell coating (microencapsulation) and natural, biocertified pig
   cells - in-house cell preparation through to manufacture.
7. LCT holds a licence to manufacture its animal cell products for human clinical use.
8. Leading patent position in key markets.

• Living Cell Technologies Ltd (LCT) is an advanced biotechnology company currently listed on the Australian Stock Exchange.
  
• LCT’s focus is on market-driven encapsulated living cell products, for the treatment of Huntington's disease, haemophilia and insulin-dependent diabetes.
  
• LCT’s business was formed in 1987 to research cell extraction
  and to develop procedures for advanced living-cell
  replacement therapies.
  
• LCT’s focus is on market-driven encapsulated living cell products, for the treatment of insulin-dependent diabetes, neurological disorders and haemophilia.
  
• Its clinical development and technology unit is in Auckland,
  New Zealand.